Uses and abuses of prescription drug information in pharmacy benefits management programs

JAMA

Volumn 283, Issue 6, 2000, Pages 801-806

  Lo, Bernard ^a,b   Alpers, Ann ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENTIALITY; DATA BASE; ETHICS; HEALTH INSURANCE; LAW; PATIENT INFORMATION; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIORITY JOURNAL; PRIVACY; REVIEW;

EID: 0033950630     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.6.801     Document Type: Review

References (47)

1. O'Harrow R. Prescription sales, privacy fears: CVS, Giant share customer records with drug marketing firm. Washington Post. February 15, 1998:A1.
2. O'Harrow R. Giant Food stops sharing customer data: prescription-marketing plan drew complaints. Washington Post. February 18, 1998:A1.
3. O'Harrow R. CVS also cuts ties to marketing service: like Giant, firm cites privacy on prescriptions. Washington Post. February 19, 1998:E1.
4. Health Insurance Portability and Accountability Act of 1996, Pub L No. 104-191, §264(c)(2), 110 Stat 1936, 2033 (1996).
5. Standards of Privacy of Individually Identifiable Health Information: Proposed Rule. 64 Federal Register 55918-60065 (1999) (codified at 45 CFR §160-164).
6. Standards of Privacy of Individually Identifiable Health Information: Proposed Rule. 64 Federal Register 59940 (1999) (codified at 45 CFR §160-164).
7. Committee on Maintaining Privacy and Security in Health Care Applications of the National Information Infrastructure. For the Record: Protecting Electronic Health Information. Washington, DC: National Academy Press; 1997.
8. Rosoff AJ. The changing face of pharmacy ben efits management: information technology pursues a grand mission. Saint Louis University Law Journal. 1998;42:1-53.
9. Lipton HL, Kreling DH, Collins T, Hertz KC. Pharmacy benefit management companies: dimensions of performance. Annu Rev Public Health. 1999;20:361-401.
10. Schulman KA, Rubenstein LE, Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: is it being evaluated? Ann Intern Med. 1996;124:906-913.
11. Lo B. Resolving Ethical Dilemmas: A Guide for Clinicians. Baltimore, Md: Williams & Wilkins; 1995.
12. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York, NY: Oxford University Press; 1994.
13. Weiss BD. Confidentiality expectations of patients, physicians, and medical students. JAMA. 1982; 247:2695-2697.
14. Health Privacy Project. The State of Health Privacy: An Uneven Terrain. Washington, DC: Institute for Health Care Research and Policy; 1999. Also available at: http://www.healthprivacy.org.
15. Gostin LO. Health information privacy. Cornell Law Review. 1995;80:451-528.
16. Hyman A, Schillinger D, Lo B. Laws mandating reporting of domestic violence: do they promote patient well-being? JAMA. 1995;273:1781-1787.
17. Appelbaum PS. Almost a Revolution: Mental Health Law and the Limits of Change. New York, NY: Oxford University Press; 1994.
18. Health Privacy Working Group. Best Principles for Health Privacy. Washington, DC: Institute for Health Care Research and Policy; 1999. Also available at: http://www.healthprivacy.org.
19. Donaldson MS, Lohr KN. Health Data in the Information Age. Washington, DC: National Academy Press; 1994:5.
20. Cal Civil Code §56-56.37 (Deering 1997).
21. O'Harrow R. Plans' access to pharmacy data raises privacy issue; benefit firms delve into patient records. Washington Post. September 27, 1998:A1.
22. As drug costs rise, health plans shift the burden. Capitation Manag Rep. 1997;4:153-158.
23. Hilzenrath DS. Between doctor and patient, a three-way relationship; adding a pharmacy benefit manager to treatment mix can bring interference, information and savings. Washington Post. August 14, 1997:E3.
24. Kolata G. Pharmacists paid to suggest drugs. New York Times. July 29, 1994:A1.
25. Kolata G. Upjohn to repay 8 states over drug plan. New York Times. August 2, 1994:01.
26. Health Policy Tracking Service of National Conference of State Legislatures. Pharmaceuticals: managed care drug formularies. Available at: http:// www.hpts.org/. Accessed October 1, 1999.
27. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
28. McCarthy R. PBMs in a jaundiced eye. Drug Benefit Trends. 1999;11:26-27.
29. Soumerai SB, Ross-Degnan D, Avom J, McLaughlin TJ, Choodnovsky I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
30. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
31. Rodwin MA. Medicine, Money, and Morals: Physicians' Conflicts of Interest. New York, NY: Oxford University Press; 1993.
32. Baker DP. Virginia bill would bar cash incentives for persuasive druggists. Washington Post. January 30, 1997:C1.
33. Pearson SD, Sabin JE, Emanuel EJ. Ethical guidelines for physician compensation based on capitation. N Engl J Med. 1998;339:689-693.
34. Latham SR. Regulation of managed care incentive payments to physicians. Am J Law Med. 1996; 22:399-432.
35. Lowrance WW. Privacy and Health Research: A Report to the U.S. Secretary of Health and Human Services. Washington, DC: Dept of Health and Human Services; 1997.
36. Goldman J. Protecting privacy to improve health care. Health Aff (Millwood). 1998;17:47-60.
37. Jimenez R. Bill would ban raids of Rx records. Boston Globe. New Hampshire edition. June 14, 1998:1.
38. Exploding pharmacy costs. On Managed Care. 1998;3:2.
39. Chassin MR, Galvin RW. The urgent need to improve health care quality: Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280:1000-1005.
40. Protection of Human Subjects, 45 CFR §46 (1998).
41. Fuller L. Consideration and form. Columbia Law Review. 1941;41:799-824.
42. National Bioethics Advisory Commission. Research on Human Stored Biologic Materials. Rockville, Md: National Bioethics Advisory Commission; 1999.
43. Thompson DF. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573-576.
44. Bayer R. Public health policy and the AIDS epidemic: an end to HIV exceptionalism? N Engl J Med. 1991;324:1500-1504.
45. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatrnent of depression. JAMA. 1997;277:333-340.
46. Notice of proposed rule making for security and electronic signature standards. Available at: http:// erm.aspe.hhs.gov/ora_web/plsql/erm_rule.rule ?user_id = &rule_id = 62. Accessed May 26, 1999.
47. National Committee for Quality Assurance. Accreditation 2000: Draft Standards for Managed Care Organizations and Managed Behavioral Health Care Organizations. Washington, DC: National Committee for Quality Assurance; 1999.